If my cancer progresses or is metastatic, what is the sequence of therapies likely to be? How do biomarker results...

Understanding Treatment Sequencing and Biomarker-Guided Therapy for Advanced Prostate Cancer

This is an excellent question that gets at the heart of modern precision oncology. Let me walk you through how doctors think about treatment sequencing and how your specific biomarkers shape the options available to you.

---

1) TREATMENT SEQUENCING FOR METASTATIC/PROGRESSIVE PROSTATE CANCER

How Oncologists Think About Treatment Order

According to NCCN Guidelines for Advanced-Stage Prostate Cancer, the treatment pathway depends heavily on whether your cancer is hormone-sensitive or has become castration-resistant (meaning it's no longer responding to hormone therapy). Here's the general framework:

Early in the disease course:

• Androgen Deprivation Therapy (ADT) - blocking testosterone - is typically the foundation. This works well initially for most men.
• Novel hormone therapies like abiraterone (Zytiga) or enzalutamide (Xtandi) are often added or used sequentially

When cancer becomes castration-resistant (CRPC): This is when your PSA rises despite low testosterone levels. At this point, doctors consider several pathways:

1. Chemotherapy - Docetaxel or cabazitaxel (which you mentioned experiencing)
2. Biomarker-targeted therapies - PARP inhibitors (if you have specific mutations)
3. Radiopharmaceuticals - Lu-PSMA or Radium-223 (if PSMA-positive)
4. Immunotherapy - Still emerging, but increasingly studied in combination approaches
5. Clinical trials - Novel combinations or single agents

The key insight from the webinar with Dr. [removed] Armstrong is that "one size fits all" treatment is outdated. Your specific genetic mutations determine which doors open for you.

---

2) HOW BIOMARKERS INFLUENCE YOUR OPTIONS

BRCA Mutations (BRCA1/BRCA2)

What it means: BRCA mutations affect your cancer cells' ability to repair damaged DNA. This creates a specific vulnerability that certain drugs can exploit.

Treatment impact: According to the PROpel trial data discussed by Dr. [removed], if you have a BRCA mutation:

• PARP inhibitors become highly effective - The combination of abiraterone + olaparib (Lynparza) showed a hazard ratio of 0.2 for BRCA-positive patients, meaning roughly an 80% reduction in progression risk
• Overall survival improvement - BRCA carriers saw approximately 7+ months improvement in overall survival (not just progression-free survival)
• This is now standard of care for BRCA-positive metastatic castration-resistant prostate cancer

The biological reasoning: Think of DNA repair like having proofreaders. BRCA genes are your "primary proofreaders." PARP is a "backup proofreader." When you block both with abiraterone + olaparib, cancer cells accumulate overwhelming DNA errors and die. Normal cells are spared because they have intact backup systems.

---

Other DNA Repair Gene Mutations (ATM, PALB2, etc.)

What it means: These genes also affect DNA repair, though through different mechanisms than BRCA.

Treatment impact: According to NCCN Guidelines, if you have mutations in these genes:

• PARP inhibitors may be effective - Options include:

  • Rucaparib (Rubraca)
  • Olaparib (Lynparza)
  • Talazoparib (Talzenna)
  • Niraparib

• Combination approaches - Often combined with androgen receptor inhibitors (like abiraterone or enzalutamide)

Important caveat: The evidence is strongest for BRCA mutations. Other DNA repair mutations show promise but may have less dramatic benefits. This is why getting comprehensive genetic testing is crucial.

---

PSMA Status (Prostate-Specific Membrane Antigen)

What it means: PSMA is a protein on the surface of prostate cancer cells. A PSMA-PET scan shows whether your cancer cells express this protein and how much.

Treatment impact: According to NCCN Guidelines, if you're PSMA-positive:

• Lu-PSMA-617 (Pluvicto) becomes an option - This is a targeted radiopharmaceutical that:

  • Finds PSMA-positive cancer cells throughout your body
  • Delivers radiation directly to them
  • Spares nearby healthy tissue
  • Given as an IV infusion once every 6 weeks for up to 6 doses

• Timing matters - You need a PSMA-PET scan first to confirm PSMA expression and determine if you're a candidate

Important consideration from the webinars: Dr. [removed] Davis emphasized the value of comparing FDG-PET scans with PSMA scans simultaneously. Why? If some lesions light up on FDG but NOT on PSMA, it may suggest a different type of cancer (like neuroendocrine transformation), which would change your treatment strategy entirely.

---

MMR Status (Mismatch Repair Deficiency)

What it means: MMR genes help fix small errors in DNA copying. When they're defective, mutations accumulate.

Treatment impact: I don't have specific prostate cancer MMR data in my current sources, but this is an area of active research. This would be an excellent question for your oncologist, as MMR status is increasingly recognized as important across cancer types.

---

3) HOW THESE BIOMARKERS INFLUENCE SEQUENCING

The Decision Tree in Practice

Here's how doctors actually use this information:

Step 1: Get comprehensive genetic testing

• Germline testing (blood test) - shows inherited mutations
• Tumor testing (tissue or liquid biopsy) - shows mutations in your cancer cells specifically
• According to Dr. [removed]: "Most men in the community are not getting any testing, especially in rural and urology practices. You should ask your doctor about getting both."

Step 2: Match biomarkers to available therapies

| Biomarker | Best Option | Timing | |---|---|---| | BRCA mutation | Abiraterone + Olaparib | Early in CRPC, before chemotherapy preferred | | Other DNA repair mutations | PARP inhibitor ± AR inhibitor | Similar timing | | PSMA-positive | Lu-PSMA | After other options, or in combination | | No specific mutations | Chemotherapy, immunotherapy trials | Standard progression |

Step 3: Consider combination approaches The field is moving toward combining therapies strategically:

• PARP inhibitor + hormone therapy
• Radiopharmaceutical + immunotherapy
• Chemotherapy + immunotherapy

---

4) IMMUNOTHERAPY AND EMERGING OPTIONS

Current status: According to Dr. [removed] Subudhi's webinar on immunotherapies, immunotherapy alone has "largely failed" in prostate cancer compared to lung or kidney cancer. However, combinations are promising:

• T-cell bispecifics - Emerging as potentially the "backbone" of future immunotherapy approaches
• Combination with radiation - Lower-dose radiation may boost immune response when combined with checkpoint inhibitors
• Bipolar Androgen Therapy (BAT) - Cycling testosterone levels; roughly 2/3 of patients see benefit (either improvement or stabilization)

Important reality check: These are still largely in clinical trials. Your oncologist can help identify which trials you might qualify for.

---

5) PRACTICAL QUESTIONS TO ASK YOUR ONCOLOGIST

Based on this framework, here are specific questions that will help you understand YOUR treatment plan:

1. "Have I had comprehensive genetic testing (both germline and tumor)? If not, can we order it now?"

   • This is foundational to everything else

2. "Based on my biomarker results, which treatment options am I eligible for?"

   • Get a clear list of what's available to you specifically

3. "What is the recommended sequence if my current treatment stops working?"

   • Understand the roadmap ahead

4. "Am I a candidate for any clinical trials?"

   • Trials often offer access to newer combinations before they're standard

5. **"If I have PSMA-positive disease, should I get a PSMA-PET scan to evaluate